JP2016528179A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528179A5 JP2016528179A5 JP2016519576A JP2016519576A JP2016528179A5 JP 2016528179 A5 JP2016528179 A5 JP 2016528179A5 JP 2016519576 A JP2016519576 A JP 2016519576A JP 2016519576 A JP2016519576 A JP 2016519576A JP 2016528179 A5 JP2016528179 A5 JP 2016528179A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- diffraction pattern
- ray diffraction
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)C(CS(C(C)*)(=O)=O)N([C@@]([C@](C[C@]1(C)C*)c2cc(*)ccc2)c(cc2)ccc2Cl)C1=O Chemical compound CC(C)C(CS(C(C)*)(=O)=O)N([C@@]([C@](C[C@]1(C)C*)c2cc(*)ccc2)c(cc2)ccc2Cl)C1=O 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020084989A JP6891322B2 (ja) | 2013-06-10 | 2020-05-14 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361833196P | 2013-06-10 | 2013-06-10 | |
| US61/833,196 | 2013-06-10 | ||
| PCT/US2014/041594 WO2014200937A1 (en) | 2013-06-10 | 2014-06-09 | Processes of making and crystalline forms of a mdm2 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020084989A Division JP6891322B2 (ja) | 2013-06-10 | 2020-05-14 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016528179A JP2016528179A (ja) | 2016-09-15 |
| JP2016528179A5 true JP2016528179A5 (enExample) | 2017-07-20 |
| JP6998655B2 JP6998655B2 (ja) | 2022-02-04 |
Family
ID=51063849
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016519576A Active JP6998655B2 (ja) | 2013-06-10 | 2014-06-09 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2020084989A Active JP6891322B2 (ja) | 2013-06-10 | 2020-05-14 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2021087378A Active JP7263439B2 (ja) | 2013-06-10 | 2021-05-25 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2023064715A Pending JP2023089126A (ja) | 2013-06-10 | 2023-04-12 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2025029906A Pending JP2025084856A (ja) | 2013-06-10 | 2025-02-27 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020084989A Active JP6891322B2 (ja) | 2013-06-10 | 2020-05-14 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2021087378A Active JP7263439B2 (ja) | 2013-06-10 | 2021-05-25 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2023064715A Pending JP2023089126A (ja) | 2013-06-10 | 2023-04-12 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
| JP2025029906A Pending JP2025084856A (ja) | 2013-06-10 | 2025-02-27 | 製造方法及びｍｄｍ２阻害剤の結晶形 |
Country Status (38)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| CA2850166C (en) | 2011-09-27 | 2019-12-03 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| EP2970237B1 (en) | 2013-03-14 | 2017-09-27 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| CN105358530A (zh) * | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| MX391859B (es) | 2013-11-11 | 2025-03-12 | Amgen Inc | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| IL319432A (en) * | 2018-04-30 | 2025-05-01 | Kartos Therapeutics Inc | Methods of treating cancer |
| AU2019273850B2 (en) | 2018-05-25 | 2024-11-14 | Kartos Therapeutics, Inc. | Methods of treating myeloproliferative neoplasms |
| BR112021003839A2 (pt) * | 2018-08-31 | 2021-07-27 | Amgen Inc. | processos para preparar um inibidor mdm2 |
| CN110963958B (zh) * | 2018-09-30 | 2025-10-10 | 上海长森药业有限公司 | 一种mdm2抑制剂，及其制备方法、药物组合物和应用 |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| US20230272001A1 (en) * | 2020-05-22 | 2023-08-31 | Merck Sharp & Dohme Llc | Novel processes for preparing conjugates of the il-2 protein |
| US20230313313A1 (en) | 2020-08-27 | 2023-10-05 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
| GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| CA3227793A1 (en) * | 2021-08-05 | 2023-02-09 | Yong Moon Choi | Phenylcarbamate crystalline form and method for manufacturing the same |
| US12054449B2 (en) | 2021-08-05 | 2024-08-06 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate crystalline form and method for manufacturing the same |
| EP4398903A4 (en) * | 2021-09-09 | 2025-07-16 | Kartos Therapeutics | METHODS FOR TREATING CANCER DEPENDENT ON MYC GENE EXPRESSION |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| CN115925589A (zh) * | 2022-12-26 | 2023-04-07 | 诚达药业股份有限公司 | 一种脂肪族亚磺酸钙盐及其制备方法 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2483213A (en) * | 1947-06-14 | 1949-09-27 | American Cyanamid Co | Alpha naphthalene sulfonic anhydride |
| CH436295A (de) | 1961-11-13 | 1967-05-31 | Mcneilab Inc | Verfahren zur Herstellung neuer 3-Morpholinone |
| US3518236A (en) * | 1967-07-20 | 1970-06-30 | Uniroyal Inc | Acceleration of sulfur-vulcanization of rubber with sulfinic acids and derivatives |
| DE3246148A1 (de) | 1982-12-14 | 1984-06-14 | Troponwerke GmbH & Co KG, 5000 Köln | Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| JP2604472B2 (ja) | 1989-07-12 | 1997-04-30 | 株式会社クラレ | 重合性組成物 |
| WO1995023135A1 (en) | 1991-03-07 | 1995-08-31 | Fisons Corporation | Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity |
| US5334720A (en) | 1991-03-07 | 1994-08-02 | Fisons Corporation | Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties |
| CA2517691A1 (en) | 1994-08-19 | 1996-02-29 | Abbott Laboratories | Endothelin antagonists |
| DK0885215T3 (da) | 1996-02-13 | 2006-08-14 | Abbott Lab | Nye benzo-1,3-dioxolyl- og benzofuranyl-substituerede pyrrolidinderivater som endthelinantagonister |
| US6159990A (en) | 1997-06-18 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Oxazolidinones as α1A receptor antagonists |
| TR200101233T2 (tr) | 1997-08-04 | 2002-06-21 | Abbott Laboratories | Endotelin antagonistleri. |
| AU1910299A (en) | 1997-12-18 | 1999-07-05 | Eli Lilly And Company | Peptidomimetic template-based combinatorial libraries |
| US6770658B2 (en) | 1998-09-09 | 2004-08-03 | Inflazyme Pharmaceuticals Ltd. | Substituted γ-phenyl-Δ-lactams and uses related thereto |
| US7214540B2 (en) * | 1999-04-06 | 2007-05-08 | Uab Research Foundation | Method for screening crystallization conditions in solution crystal growth |
| US6630006B2 (en) * | 1999-06-18 | 2003-10-07 | The Regents Of The University Of California | Method for screening microcrystallizations for crystal formation |
| US7195670B2 (en) * | 2000-06-27 | 2007-03-27 | California Institute Of Technology | High throughput screening of crystallization of materials |
| US7052545B2 (en) * | 2001-04-06 | 2006-05-30 | California Institute Of Technology | High throughput screening of crystallization of materials |
| DE19951418A1 (de) * | 1999-10-26 | 2001-05-03 | Merck Patent Gmbh | Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid |
| WO2002017912A1 (en) | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
| WO2002042731A2 (en) * | 2000-11-20 | 2002-05-30 | Parallel Synthesis Technologies, Inc. | Methods and devices for high throughput crystallization |
| CA2436774A1 (en) | 2001-01-30 | 2002-08-08 | R. Michael Lawrence | Sulfonamide lactam inhibitors of factor xa |
| ATE409181T1 (de) | 2001-05-08 | 2008-10-15 | Univ Yale | Proteomimetische verbindungen und verfahren |
| WO2002094787A1 (en) | 2001-05-23 | 2002-11-28 | Ucb, S.A. | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders |
| DE60225719T2 (de) | 2001-12-18 | 2009-04-23 | F. Hoffmann-La Roche Ag | Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren |
| US6860940B2 (en) * | 2002-02-11 | 2005-03-01 | The Regents Of The University Of California | Automated macromolecular crystallization screening |
| US6916833B2 (en) * | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| MXPA06013246A (es) | 2004-05-18 | 2007-02-08 | Hoffmann La Roche | Nuevas imidazolinas cis. |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| JP2007297283A (ja) | 2004-07-28 | 2007-11-15 | Santen Pharmaceut Co Ltd | 新規桂皮酸関連化合物 |
| EP1809282B1 (en) | 2004-10-18 | 2013-01-09 | Amgen, Inc | Thiadiazole compounds and methods of use |
| AU2006215041B2 (en) | 2005-02-18 | 2012-05-31 | Mitsubishi Tanabe Pharma Corporation | Salt of proline derivative, solvate thereof, and production method thereof |
| US7579368B2 (en) | 2005-03-16 | 2009-08-25 | Hoffman-La Roche Inc. | Cis-imidazolines |
| CA2603258A1 (en) | 2005-04-04 | 2006-10-12 | Eisai Co., Ltd. | Dihydropyridine compounds and compositions for headaches |
| JP5284779B2 (ja) | 2005-06-07 | 2013-09-11 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | コンジュゲート化された向精神薬の新規な塩およびその調製方法 |
| WO2007015929A2 (en) | 2005-07-27 | 2007-02-08 | University Of Toledo | Epothilone analogues |
| EP2311814A1 (en) | 2005-12-01 | 2011-04-20 | F. Hoffmann-La Roche AG | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents |
| EP1981884B1 (en) | 2006-01-18 | 2012-06-13 | Amgen, Inc | Thiazole compounds as protein kinase b (pkb) inhibitors |
| US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
| CN101595107A (zh) | 2006-06-30 | 2009-12-02 | 先灵公司 | 能提高p53活性的有取代哌啶及其用途 |
| WO2008010953A2 (en) | 2006-07-19 | 2008-01-24 | University Of Georgia Research Foundation, Inc. | Pyridinone diketo acids: inhibitors of hiv replication in combination therapy |
| US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
| WO2008021338A2 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Tricyclic oxazolidone derivatives useful as pr modulators |
| TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| GB0722769D0 (en) | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
| US7705018B2 (en) | 2007-03-23 | 2010-04-27 | Amgen Inc. | Substituted quinolines and their uses in treatment of inflammatory and related conditions |
| EP2132207A2 (en) | 2007-03-23 | 2009-12-16 | Amgen Inc. | Heterocyclic compounds and their uses |
| AU2008231304B2 (en) | 2007-03-23 | 2011-05-12 | Amgen Inc. | Heterocyclic compounds and their uses |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
| US7834179B2 (en) | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| EA018708B1 (ru) | 2007-07-09 | 2013-10-30 | Астразенека Аб | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K |
| WO2009011871A2 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
| WO2009011880A2 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
| ES2401557T3 (es) | 2007-08-02 | 2013-04-22 | Amgen, Inc | Moduladores de Pl3 cinasas y métodos de uso |
| MX2010003868A (es) | 2007-10-09 | 2010-04-27 | Hoffmann La Roche | Cis-imidazolinas quirales. |
| CL2008003798A1 (es) | 2007-12-19 | 2009-10-09 | Amgen Inc | Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades. |
| US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| US20100256191A1 (en) | 2007-12-26 | 2010-10-07 | Eisai R&D Management Co., Ltd. | Ampa receptor antagonists and zonisamide for epilepsy |
| WO2009114950A1 (en) | 2008-03-21 | 2009-09-24 | Chlorion Pharma, Inc. | Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain |
| EP2307400B1 (en) | 2008-05-30 | 2014-04-23 | Amgen, Inc | Inhibitors of pi3 kinase |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| WO2010030704A2 (en) | 2008-09-10 | 2010-03-18 | Achaogen, Inc. | Antibacterial aminoglycoside analogs |
| AR073578A1 (es) | 2008-09-15 | 2010-11-17 | Priaxon Ag | Pirrolidin-2-onas |
| PE20110367A1 (es) | 2008-09-18 | 2011-06-13 | Hoffmann La Roche | DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2 |
| US20110263647A1 (en) | 2009-01-15 | 2011-10-27 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
| WO2010096314A1 (en) | 2009-02-18 | 2010-08-26 | Amgen Inc. | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS |
| JP2012521354A (ja) | 2009-03-20 | 2012-09-13 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| WO2010132598A1 (en) | 2009-05-13 | 2010-11-18 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| JP2012531436A (ja) | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | 複素環式化合物およびそれらのｐｉ３ｋ活性阻害剤としての使用 |
| UY32743A (es) | 2009-06-25 | 2010-12-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| MX2011013666A (es) | 2009-06-25 | 2012-03-06 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| US8754089B2 (en) | 2009-06-25 | 2014-06-17 | Amgen Inc. | Heterocyclic compounds and their uses |
| IN2012DN01693A (enExample) | 2009-08-26 | 2015-06-05 | Novartis Ag | |
| WO2011044501A2 (en) | 2009-10-09 | 2011-04-14 | Achaogen, Inc. | Antibacterial aminoglycoside analogs |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| TW201137923A (en) * | 2010-02-10 | 2011-11-01 | Halcyon Molecular Inc | Aberration-correcting dark-field electron microscopy |
| IT1399923B1 (it) | 2010-05-11 | 2013-05-09 | Cbb Net S A | Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| KR20180080358A (ko) | 2011-01-10 | 2018-07-11 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀린온 및 이의 고체 형태의 제조 방법 |
| CN102153557B (zh) | 2011-01-21 | 2013-03-20 | 中国科学院上海有机化学研究所 | 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途 |
| WO2012147953A1 (ja) * | 2011-04-28 | 2012-11-01 | 大塚化学株式会社 | アゾジカルボンアミドの新規製造法 |
| TW201309651A (zh) | 2011-06-29 | 2013-03-01 | Otsuka Pharma Co Ltd | 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法 |
| CA2850166C (en) | 2011-09-27 | 2019-12-03 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
| CN103373951B (zh) * | 2012-04-28 | 2016-03-09 | 上海医药工业研究院 | 一种拉帕替尼中间体的制备方法 |
| WO2014130470A1 (en) | 2013-02-19 | 2014-08-28 | Amgen Inc. | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer |
| WO2014134201A1 (en) | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| EP2970237B1 (en) | 2013-03-14 | 2017-09-27 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| CN105358530A (zh) | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
-
2014
- 2014-06-09 CN CN201480033215.1A patent/CN105358530A/zh active Pending
- 2014-06-09 LT LTEP14735785.9T patent/LT3008039T/lt unknown
- 2014-06-09 RS RS20201515A patent/RS61192B1/sr unknown
- 2014-06-09 EA EA201592305A patent/EA031254B1/ru unknown
- 2014-06-09 MY MYPI2019006678A patent/MY205257A/en unknown
- 2014-06-09 EP EP14735785.9A patent/EP3008039B1/en active Active
- 2014-06-09 UA UAA201600159A patent/UA121301C2/uk unknown
- 2014-06-09 TN TN2015000521A patent/TN2015000521A1/en unknown
- 2014-06-09 KR KR1020217030265A patent/KR20210121270A/ko not_active Ceased
- 2014-06-09 CN CN201811222652.4A patent/CN110003092A/zh active Pending
- 2014-06-09 WO PCT/US2014/041594 patent/WO2014200937A1/en not_active Ceased
- 2014-06-09 SM SM20210013T patent/SMT202100013T1/it unknown
- 2014-06-09 KR KR1020247035781A patent/KR20240159641A/ko active Pending
- 2014-06-09 HR HRP20202065TT patent/HRP20202065T1/hr unknown
- 2014-06-09 KR KR1020237002549A patent/KR20230019216A/ko not_active Ceased
- 2014-06-09 JP JP2016519576A patent/JP6998655B2/ja active Active
- 2014-06-09 CA CA3200532A patent/CA3200532A1/en active Pending
- 2014-06-09 MX MX2019012007A patent/MX379872B/es unknown
- 2014-06-09 EP EP20197741.0A patent/EP3805232A1/en active Pending
- 2014-06-09 ES ES14735785T patent/ES2851023T3/es active Active
- 2014-06-09 SG SG11201509896VA patent/SG11201509896VA/en unknown
- 2014-06-09 MX MX2015016856A patent/MX2015016856A/es unknown
- 2014-06-09 PE PE2015002561A patent/PE20160113A1/es unknown
- 2014-06-09 PL PL14735785T patent/PL3008039T3/pl unknown
- 2014-06-09 BR BR112015031004-4A patent/BR112015031004B1/pt active IP Right Grant
- 2014-06-09 AU AU2014278428A patent/AU2014278428B2/en active Active
- 2014-06-09 MA MA53572A patent/MA53572A1/fr unknown
- 2014-06-09 PH PH1/2020/550916A patent/PH12020550916A1/en unknown
- 2014-06-09 PE PE2020000392A patent/PE20210153A1/es unknown
- 2014-06-09 AP AP2015008891A patent/AP2015008891A0/xx unknown
- 2014-06-09 UA UAA202000229A patent/UA129695C2/uk unknown
- 2014-06-09 SG SG10201801402XA patent/SG10201801402XA/en unknown
- 2014-06-09 KR KR1020157036194A patent/KR20160018576A/ko not_active Ceased
- 2014-06-09 SI SI201431735T patent/SI3008039T1/sl unknown
- 2014-06-09 PT PT147357859T patent/PT3008039T/pt unknown
- 2014-06-09 IL IL297860A patent/IL297860A/en unknown
- 2014-06-09 CA CA3115609A patent/CA3115609C/en active Active
- 2014-06-09 BR BR122020003153-0A patent/BR122020003153B1/pt active IP Right Grant
- 2014-06-09 EA EA202091612A patent/EA202091612A1/ru unknown
- 2014-06-09 EA EA201891642A patent/EA201891642A1/ru unknown
- 2014-06-09 HU HUE14735785A patent/HUE053047T2/hu unknown
- 2014-06-09 MA MA38714A patent/MA38714A1/fr unknown
- 2014-06-09 CR CR20210290A patent/CR20210290A/es unknown
- 2014-06-09 CA CA3201958A patent/CA3201958A1/en active Pending
- 2014-06-09 MY MYPI2015002896A patent/MY194848A/en unknown
- 2014-06-09 CN CN201910783352.1A patent/CN110627708A/zh active Pending
- 2014-06-09 CA CA2914723A patent/CA2914723C/en active Active
- 2014-06-09 NZ NZ714821A patent/NZ714821A/en unknown
- 2014-06-09 DK DK14735785.9T patent/DK3008039T3/da active
- 2014-06-10 US US14/301,087 patent/US9376386B2/en active Active
- 2014-06-10 TW TW107134691A patent/TWI698428B/zh active
- 2014-06-10 UY UY0001035605A patent/UY35605A/es not_active Application Discontinuation
- 2014-06-10 AR ARP140102235A patent/AR096582A1/es not_active Application Discontinuation
- 2014-06-10 TW TW109118829A patent/TWI791153B/zh active
- 2014-06-10 JO JOP/2014/0186A patent/JO3768B1/ar active
- 2014-06-10 TW TW103120104A patent/TWI649306B/zh active
- 2014-06-10 UY UY0001040179A patent/UY40179A/es not_active Application Discontinuation
-
2015
- 2015-11-16 IL IL242622A patent/IL242622B/en active IP Right Grant
- 2015-12-03 PH PH12015502705A patent/PH12015502705B1/en unknown
- 2015-12-10 CL CL2015003589A patent/CL2015003589A1/es unknown
- 2015-12-23 MA MA43288A patent/MA43288B1/fr unknown
-
2016
- 2016-01-07 CR CR20160010A patent/CR20160010A/es unknown
- 2016-05-24 US US15/163,186 patent/US9855259B2/en active Active
- 2016-06-07 US US15/175,798 patent/US20160287570A1/en not_active Abandoned
- 2016-06-07 US US15/175,805 patent/US9623018B2/en active Active
- 2016-06-07 US US15/175,824 patent/US9801867B2/en active Active
- 2016-06-07 US US15/175,821 patent/US9757367B2/en active Active
-
2017
- 2017-11-22 US US15/820,830 patent/US20180092898A1/en not_active Abandoned
-
2018
- 2018-11-07 AU AU2018260844A patent/AU2018260844B2/en active Active
-
2019
- 2019-01-08 CL CL2019000056A patent/CL2019000056A1/es unknown
- 2019-05-07 IL IL266504A patent/IL266504B/en active IP Right Grant
- 2019-10-25 US US16/664,103 patent/US20200281912A1/en not_active Abandoned
-
2020
- 2020-04-28 AR ARP200101191A patent/AR119727A2/es active IP Right Grant
- 2020-05-14 JP JP2020084989A patent/JP6891322B2/ja active Active
- 2020-11-10 AU AU2020267169A patent/AU2020267169B2/en active Active
- 2020-11-22 JO JOP/2020/0296A patent/JOP20200296A1/ar unknown
- 2020-12-18 CY CY20201101201T patent/CY1123661T1/el unknown
-
2021
- 2021-03-08 CL CL2021000566A patent/CL2021000566A1/es unknown
- 2021-03-25 IL IL281807A patent/IL281807B2/en unknown
- 2021-05-25 JP JP2021087378A patent/JP7263439B2/ja active Active
- 2021-10-13 US US17/500,039 patent/US20220280496A1/en not_active Abandoned
-
2022
- 2022-11-16 AU AU2022271425A patent/AU2022271425B2/en active Active
-
2023
- 2023-04-12 JP JP2023064715A patent/JP2023089126A/ja active Pending
- 2023-05-08 US US18/313,428 patent/US20230301974A1/en not_active Abandoned
-
2024
- 2024-06-03 AR ARP240101415A patent/AR132854A2/es unknown
- 2024-09-02 AU AU2024216533A patent/AU2024216533A1/en active Pending
-
2025
- 2025-02-27 JP JP2025029906A patent/JP2025084856A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528179A5 (enExample) | ||
| JP2017061547A5 (enExample) | ||
| RU2019101220A (ru) | Кристаллические формы соединения триазолопиримидина | |
| JP2016128501A5 (enExample) | ||
| JP2022049005A5 (enExample) | ||
| JP2022186995A5 (enExample) | ||
| JP5070364B2 (ja) | ６，７−不飽和−７−カルバモイルモルヒナン誘導体の結晶およびその製造方法 | |
| RU2537319C2 (ru) | Способы изготовления и назначение деривата sphaelactone и его композитные лекарства | |
| JP2021530565A5 (enExample) | ||
| JP2019528276A5 (enExample) | ||
| JP2018515490A5 (enExample) | ||
| JP2006528973A5 (enExample) | ||
| JP2015512942A5 (enExample) | ||
| JP2011126896A5 (enExample) | ||
| JP2018531280A5 (enExample) | ||
| JP2020535168A5 (enExample) | ||
| JP7257328B2 (ja) | ベンゾフラン誘導体遊離塩基の結晶およびその製造方法 | |
| PT1296951E (pt) | 5-cloro-3-(4-metanossulfonilfenil)-6'-metil-[2,3'] bipiridinilo na forma cristalina pura e processo para sua síntese | |
| RU2012136148A (ru) | Новая кристаллическая форма производного циклопропилбензамида | |
| JP2016537326A5 (enExample) | ||
| JP2010514725A5 (enExample) | ||
| JP2011515421A5 (enExample) | ||
| JP2016510767A5 (enExample) | ||
| BR112020002892A2 (pt) | forma sólida de 3-(5-flúor-benzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5-f]indol-7-il)pirrol-2,5-diona, processo para preparar a forma sólida, composição farmacêutica, processo para preparar uma composição farmacêutica, método para tratar câncer em um paciente e método para tratar lesão cerebral traumática em um paciente | |
| JPWO2020210669A5 (enExample) |